The aforementioned studies indicate that LIQ exhibits dual functionality in breast cancer, wherein it sometimes suppresses tumor growth by acting as an ERβ agonist, yet, paradoxically, it promotes cell proliferation, probably due to unspecific activation of ERα and its estrogenic activity. Here, ESR1 is linked to breast carcinoma.